Kura Oncology Inc at Bank of America Global Healthcare Conference Transcript
(audio in progress) Kura. Troy Wilson, CEO and Brian Powl. Thank you so much for joining us.
Thank you, Jason.
Questions & Answers
Maybe to start broadly for those less familiar with Kura's story, could you please provide a brief overview of zifto and darli?
Sure, yeah. So on one side, you have ziftomenib or commercial name, KOMZIFTI. We have approval in the relapsed refractory in NPM1-mutant setting. Our goal is to be the market leader to drive sustainable quarter-over-quarter growth there. We have a, I think, the largest most comprehensive Phase 3 development program for both the intensive and non-intensive frontline setting. We'll be giving a data update
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
